TOGGLE MENU TOGGLE SEARCH HOME INVESTORS NEWSROOM Freeline to Participate in Stifel 2021 Virtual Healthcare Conference Published 10 November 2021 Share this article: LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will participate in the Stifel 2021 Virtual Healthcare Conference. Freeline Chief Executive Officer Michael Parini is scheduled to participate in a Fireside Chat at the event on November 15, 2021 at 1:20 p.m. ET. A webcast of the Fireside Chat will be available on the Investors section of the Freeline website for 90 days. Senior management will participate in virtual one-on-one meetings with investors at the conference on November 16. About Freeline Therapeutics Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally-designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream. The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease Type 1 and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US. Contact David S. Arrington Vice President Investor Relations & Corporate Communications Freeline Therapeutics david.arrington@freeline.life +1 (646) 668 6947 Published 10 November 2021 Share this article: PRINT/SAVE ARTICLE READ THIS NEXT Freeline to Participate in Evercore ISI 4th Annual HealthCONx Conference 23 November 2021 LONDON, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today READ FULL STORY Freeline Reports New Data from Fabry Disease Program, Pipeline and Company Updates, Including Appointment of Pamela Foulds, MD as Chief Medical Officer, and Third Quarter 2021 Financial Results 09 November 2021 Freeline today announced new data from its ongoing Phase 1/2 MARVEL-1 dose-finding clinical trial of FLT190 for the treatment of Fabry disease and provided updates on its pipeline programs. The Company also announced that Pamela Foulds, MD has been appointed as Chief Medical Officer (CMO) and reported financial results for the third quarter of 2021. READ FULL STORY For all media enquiries please get in touch media@freeline.life Get in touch T. Telephone: +44 (0)1438 906870 E. Email: contact@freeline.life Follow us on our social channels About us Innovation Patients & families Healthcare professionals Careers Investors Contact Terms of use Privacy Notice Accessibility Cookie Policy ©2021 Freeline